Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011
Upcoming SlideShare
Loading in...5
×
 

Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011

on

  • 210 views

 

Statistics

Views

Total Views
210
Views on SlideShare
210
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011 Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011 Document Transcript

  • Market and Product Forecasts: Top 20 Oncology TherapyBrands 2011-21 - Avastin fails to top any individual market in2011Report Details:Published:September 2012No. of Pages: 47Price: Single User License – US$11400The high level of commercial success experienced by the key companies in the cancer therapymarket makes the market extremely attractive to drug developers. Treatment of cancer has shiftedtoward a more focused attack on the disease with targeted therapies. However, austeritypackages imposed could see slower commercial growth and larger generic erosion of key brands.Features and Benefits•Analysis of the top 20 oncology therapy brands in the seven major markets•In depth analysis of the factors influencing the top 20 oncology brands in individual countries of the seven major markets•Sales forecasts for the top 20 cancer therapy brands from 2011 to 2021•Brand dynamics and assessment of the top 5 cancer brands in the seven major marketsHighlightsThe total sales of the top 20 cancer therapy brands in the seven major markets was $37.2bn in2011, with targeted therapies representing 74% of those sales. However, the oncology market isfragmenting as developers focus on niche subsets of patients with specific genetic mutations,making it harder for drugs to reach blockbuster status.Targeted therapies dominated the market, and will increase their share of the top 20 as patentexpiries continue to impact sales of other drug classes. Generic erosion of multiple key brands inthe cytotoxic class will be the key driver in decreasing its share of the top 20 branded sales from17% in 2011 to 10% in 2021.Avastin did not achieve the top position in any of the individual markets, the US, Japan, or 5EU,due to a combination of US indication removal, cost-conservative EU markets, strongantihormonal sales in Japan, and tough Swiss Franc exchange rates.Your key questions answered
  • •Quantify the performance of each of the top 20 cancer therapy brands in the seven major markets in 2011 and 2021.•Acquire an account of top-selling cancer brand dynamics and the events that drive and limit their market growth.•The report is accompanied by a PowerPoint presentation and Excel deliverable showing full top 20 forecasts for the US, Japan and 5EU.Get your copy of this report @http://www.reportsnreports.com/reports/191886-market-and-product-forecasts-top-20-oncology-therapy-brands-2011-21-avastin-fails-to-top-any-individual-market-in-2011.htmlMajor points covered in Table of Contents of this report include OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Market definition for cancer therapies Antihormonal therapies by ATC class Cytotoxic therapies by ATC class Targeted therapies by ATC class Forecast methodology and assumptions Methodology flow Patent expiries Additional forecast methodology MARKET OVERVIEW AND CONTEXT Cancer therapy brands included in this report Seven major markets top 20 oncology therapy brands Targeted therapies will continue to control the seven major markets top 20 US top 20 oncology therapy brands Cytotoxic brands lose out following patent expiries as targeted therapies fragment themarket Japan top 20 oncology therapy brands Patent expiries are likely to become more significant over the forecast period Five major EU markets top 20 oncology therapy brands Economic constraints limit sales growth of targeted therapies PRODUCT FORECASTS Brand dynamics Avastin maintains overall leading position despite not topping any of the markets in 2011
  • Avastin (bevacizumab; Roche/Chugai) Forecast assumptions Avastin forecast 2011–21 Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo) Forecast assumptions Rituxan forecast 2011–21 Herceptin (trastuzumab; Roche/Chugai) Forecast assumptions Herceptin forecast 2011–21 Gleevec (imatinib; Novartis) Forecast assumptions Gleevec forecast 2011–21 Revlimid (lenalidomide; Celgene) Forecast assumptions Revlimid forecast 2011–21 Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) Forecast assumptions Erbitux forecast 2011–21 Lupron (leuprolide; Takeda/Abbott) Forecast assumptions Lupron forecast 2011–21 BIBLIOGRAPHY Journal papers Websites Datamonitor reports APPENDIX Forecast methodology Volume and value forecast methodology Price assumptions TABLES Table: Definition of the cancer market, 2012 Table: Patent expiry dates for antihormonal therapies in the top 20, 2011–21 Table: Patent expiry dates for cytotoxic therapies in the top 20, 2011–21 Table: Patent expiry dates for targeted therapies in the top 20, 2011–21 Table: Drugs included in the top 20 cancer therapy brands, 2011–21 Table: Sales of the top 20 cancer therapy brands in the seven major markets ($m), 2011 Table: Forecast sales of the top 20 cancer therapy brands in the seven major markets ($m),2011–21 Table: Sales of the top 20 cancer therapy brands in the US, 2011 Table: Forecast sales of the top 20 cancer therapy brands in the US ($m), 2011–21 Table: Sales of the top 20 cancer therapy brands in Japan, 2011 Table: Forecast sales of the top 20 cancer therapy brands in Japan ($m), 2011–21
  • Table: Sales of the top 20 cancer therapy brands in the five major EU markets, 2011 Table: Forecast sales of the top 20 cancer therapy brands in the five major EU markets ($m),2011–21 Table: Key branded cancer therapy sales in the seven major markets, 2011 and 2021 Table: Avastin sales, by market ($m), 2011–21 Table: Rituxan sales, by market ($m), 2011–21 Table: Herceptin sales, by market ($m), 2011–21 Table: Gleevec sales, by market ($m), 2011–21 Table: Revlimid sales, by market ($m), 2011–21 Table: Erbitux sales, by market ($m), 2011–21 Table: Lupron sales, by market ($m), 2011–21 FIGURES Figure: Company-reported sales-based forecast methodology, 2012 Figure: Unevented and evented company-reported sales-based forecasts Figure: Sales of the top 20 cancer therapy brands in the seven major markets, by drug class($m), 2011 and 2021 Figure: Sales of the top 20 cancer therapy brands in the US, by drug class ($m), 2011 and2021 Figure: Sales of the top 20 cancer therapy brands in Japan, by drug class ($m), 2011 and2021 Figure: Sales of the top 20 cancer therapy brands in the five major EU markets by drug class($m), 2011 and 2021 Figure: Key branded drug sales, 2011–21 Figure: Avastin sales, by market ($m), 2011–21 Figure: Rituxan sales, by market ($m), 2011–21 Figure: Herceptin sales, by market ($m), 2011–21 Figure: Gleevec sales, by market ($m), 2011–21 Figure: Revlimid sales, by market ($m), 2011–21 Figure: Erbitux sales, by market ($m), 2011–21 Figure: Lupron sales, by market ($m), 2011–21Contact: sales@reportsandreports.com for more information.